1. Protein Tyrosine Kinase/RTK
  2. VEGFR

VEGFR

VEGFRs consist of three subtypes, the fms-like tyrosine kinase Flt-1 (VEGFR1/Flt-1), the kinase domain region, also referred to as fetal liver kinase (VEGFR2/KDR/Flk-1), and Flt-4 (VEGFR3). Each receptor has seven immunoglobulinlike domains in the extracellular domain, a single transmembrane region, and a consensus tyrosine kinase sequence interrupted by a kinase insert domain. VEGFR1 and 2 are expressed on vascular endothelial cells, whereas VEGFR3 is expressed on lymphatic endothelial. The VEGF family members VEGF-A, -B, -C, -D, -E, and PlGF, and the human immunodeficiency (HIV) Tat protein bind in specific patterns to three related receptor protein tyrosine kinases, VEGFR1, 2, and 3, and induce the formation of homo- and heteromeric receptor complexes. Binding of VEGF to VEGFR causes dimerization and autophosphorylation of the receptor. Intracellular proteins such as VEGFR-associated protein (VRAP), PLC, and Sck that associate with specific tyrosine residues of VEGFR are phosphorylated upon receptor activation. Several signal transduction pathways are activated by the binding of VEGF to its receptor, leading to increased proliferation, survival, permeability, and migration of cells.

VEGFR Isoform Specific Products:

  • VEGFR1/Flt-1

  • VEGFR2/KDR/Flk-1

  • VEGFR3/Flt-4

VEGFR 相关产品 (107):

Cat. No. Product Name Effect Purity
  • HY-10201
    Sorafenib Inhibitor 99.92%
    Sorafenib (Bay 43-9006) 是有效的多激酶抑制剂,抑制Raf-1B-RafVEGFR-3IC50 分别为6 nM,20 nM,22 nM。
  • HY-10981
    Lenvatinib Inhibitor 99.59%
    Lenvatinib是一种口服,多靶点酪氨酸激酶抑制剂,抑制 VEGFR2(KDR)VEGFR3(Flt-4)IC50 分别为 4 和 5.2 nM。
  • HY-10331
    Regorafenib Inhibitor 99.95%
    Regorafenib (BAY 73-4506) 是一种多靶点受体酪氨酸激酶抑制剂,抑制VEGFR1/2/3PDGFRβKitRETRaf-1IC50 分别为13/4.2/46,22,7,1.5 和2.5 nM。
  • HY-50904
    Nintedanib Inhibitor 99.97%
    Nintedanib (BIBF 1120) 是一种有效的三重血管激酶抑制剂,抑制 VEGFR1/2/3FGFR1/2/3PDGFRα/βIC50 值分别为 34 nM/13 nM/13 nM,69 nM/37 nM/108 nM 和 59 nM/65 nM。
  • HY-13016
    Cabozantinib Inhibitor 99.92%
    Cabozantinib是一种有效的多受体酪氨酸激酶抑制剂, 抑制VEGFR2c-MetKitAxlFlt3IC50 分别为0.035,1.3,4.6,7 和 11.3 nM。
  • HY-12423A
    TAS-115 mesylate Inhibitor 99.15%
    TAS-115 mesylate是一种有效的 VEGFR 和肝细胞生长因子受体 (c-Met/HGFR) 的靶向激酶抑制剂,能够抑制 rVEGFR2 和 rMET 的活性,IC50 值分别为 30 和 32 nM。
  • HY-12047
    Ponatinib Inhibitor 98.96%
    Ponatinib是一种有效的,可口服的多靶点激酶抑制剂,抑制AblPDGFRαVEGFR2FGFR1SrcIC50 分别为0.37 nM, 1.1 nM,1.5 nM,2.2 nM和5.4 nM。
  • HY-10255A
    Sunitinib Inhibitor 99.66%
    Sunitinib (SU 11248)是一种多靶点受体酪氨酸激酶抑制剂,抑制VEGFR2PDGFRβIC50 分别为80 nM 和 2 nM。
  • HY-10374
    Semaxinib Inhibitor 99.93%
    Semaxinib (SU5416) 是有效,选择性的 VEGFR (Flk-1/KDR) 抑制剂,IC50 为1.23 μM。
  • HY-10201A
    Sorafenib Tosylate Inhibitor 99.53%
    Sorafenib tosylate是一种有效的多激酶抑制剂,抑制Raf-1B-RafVEGFR-3IC50 分别为6 nM,20 nM 和 22 nM。
  • HY-P9906
    Bevacizumab Inhibitor >99.0%
    Bevacizumab 是一种人源化的单克隆抗体,高亲和力且特异性地与所有 VEGF-A 结合。
  • HY-13342
    Apatinib Inhibitor 99.93%
    Apatinib 是一种高选择性的 VEGFR2 抑制剂,IC50 为 1 nM。Apatinib也有效抑制Ret,c-Kit 和 c-Src活性,IC50s分别为 13,429 和 530 nM。
  • HY-10260
    Vandetanib Inhibitor 99.89%
    Vandetanib是有效的 VEGFR2 抑制剂,IC50 为40 nM。
  • HY-10208
    Pazopanib Inhibitor 99.68%
    Pazopanib (GW786034) 是多靶点抑制剂,抑制 VEGFR1VEGFR2VEGFR3PDGFRβc-KitFGFR1c-FmsIC50分别为10,30,47,84,74,140,146 nM。
  • HY-10255
    Sunitinib Malate Inhibitor 99.47%
    Sunitinib Malate (SU 11248 Malate) 是一种有效的酪氨酸激酶抑制剂, 抑制 VEGFR2PDGFRβIC50 分别为 80 nM 和 2 nM。
  • HY-10065
    Axitinib Inhibitor 99.94%
    Axitinib是多靶点的酪氨酸激酶抑制剂,抑制 VEGFR1VEGFR2VEGFR3 PDGFRβIC50 值分别为4,20,4,2 nM。
  • HY-10321
    PD173074 Inhibitor 99.55%
    PD173074 是有效的 FGFR1 抑制剂,IC50 为 25 nM;也可抑制 VEGFR2 的活性,IC50 值为 100-200 nM,对 FGFR1 的活性是 PDGFR 和 c-Src 的1000多倍。
  • HY-10338
    Foretinib Inhibitor 99.81%
    Foretinib是一种多靶点酪氨酸激酶抑制剂,抑制 MetKDRIC50分别为0.4 nM 和 0.9 nM。
  • HY-10407
    SU 5402 Inhibitor 99.23%
    SU 5402 是一种有效的多靶点受体酪氨酸激酶抑制剂,作用于 VEGFR2FGFR1PDGFRβIC50 分别为 20 nM,30 nM 和 510 nM。
  • HY-50751
    Linifanib Inhibitor 99.60%
    Linifanib (ABT-869) 是一种多靶点 VEGFPDGFR 受体家族的抑制剂,抑制KDR,Flt-1,PDGFRβ和FLT3的 IC50 值分别为3,4,66,4 nM。
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.